ReviewCommunications biology2026
Unveiling the sensing potential of innate lymphoid cells.
Review in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Innate lymphoid cells (ILCs) are key regulators of early immune responses and play a central role in mucosal immunity, where they contribute to host defense and tissue homoeostasis. This review synthesizes evidence that ILCs, including natural killer cells (NKs), ILC1s, ILC2s, ILC3s, and lymphoid tissue inducer (LTi) cells, directly sense pathogens via pattern recognition receptors (PRRs). Beyond their established role as cytokine responders, emerging data reveal that ILCs engage PRRs to initiate complementary, context-dependent signaling pathways. This direct recognition mechanism redefines the functional landscape of ILCs in early immune surveillance, moving beyond reliance on indirect stromal signals. Collectively, these insights reposition ILCs as active sentinels in host defense and highlight the ILC-PRR axis as a novel therapeutic avenue for modulating immune responses in infectious, inflammatory, and cancer-related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.